AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$ABEO

O'Malley Brendan M. sold $35K of ABEO

O'Malley Brendan M. (SVP, Chief Legal Officer) sold 6,727 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.16 on 2026-09-29.

Original reporting
SEC EDGAR · O'Malley Brendan M.
Published Sep 30, 2026, 1:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Bearish
medium confidence
Mentioned
$ABEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEOBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price weakness, though the amount is modest.

02

Market read

Primary relevance is the insider sell; limited broader market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filing reports an insider transaction by Abeona Therapeutics' senior legal officer.

Company-level read

Ticker impact

$ABEOBearishMedium confidence
Context

Form 4 disclosed SVP/Chief Legal Officer sold 6,727 shares for $34,682, a direct insider sale.

Expected impact

likely slight downward pressure as market prices in the insider sell

Evidence & confidence

C‑level insider sold shares worth ~ $35K; while modest, such sales are often viewed negatively by traders.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated insider transaction.

Regional

No significant regional effect.

Global

Limited to investors tracking Abeona Therapeutics.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Abeona Therapeutics Inc.

    Biopharmaceutical company developing gene‑editing therapies.

  • Individual
    Brendan M. O'Malley

    SVP and Chief Legal Officer of Abeona, reported insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min